Latest News
All Times Eastern
- Barron's PacWest Stock Climbs After Dividend Cut. Other Regional Banks Are Rising Too.
- Three questions that can help you decide if your business idea is a winner or a dud
- Why the used car market could get worse for buyers. What will reverse the pattern?
- Here are some of the most advanced car tech features you should know about
- 50th high school reunion? No thanks. Here’s why I’m not going.
- A different spin on ‘retail therapy’ can help you manage rising financial anxieties
- Barron's Occidental, Berkshire Hathaway, PacWest, AMC, PayPal, and More Stock Market Movers
- PacWest shares jump 12% in premarket after lender says it’s cutting dividend
- Barron's Is a Credit Crunch Coming? We'll Get Some Clues on Monday.
- German industrial production fell in March as car manufacturing slumped
to be replaced
Bio-Rad Laboratories Inc. Cl A
BIOUS
$
2.73
0.71%
After Hours
$
387.97
After Hours Volume:
2.62K
| Close | Chg | Chg % |
|---|---|---|
| $385.24 | -77.37 | -16.72% |
Volume: 839.09K
65 Day Avg: 170.2K
373.07
Day Range
400.00
344.63
52 Week Range
572.70
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
BIO Overview
Key Data
- Open $400.00
- Day Range 373.07 - 400.00
- 52 Week Range 344.63 - 572.70
- Market Cap $11.4B
- Shares Outstanding 24.52M
- Public Float 20.94M
- Beta 0.85
- Rev. per Employee $338.91K
- P/E Ratio N/A
- EPS -$6.54
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 274.42K 04/14/23
- % of Float Shorted 1.31%
- Average Volume 170.2K
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 6
Full Ratings
Recent News
Bio-Rad Laboratories started at hold with $195 stock price target at Deutsche Bank
SEC charges Bio-Rad Laboratories with bribery violations
WASHINGTON (MarketWatch)--The Securities and Exchange Commission charged Bio-Rad Laboratories , a clinical diagnostic and life-science research company, with violating the Foreign Corrupt Practices Act. According to the SE...
Bio-Rad jumps 12% on Luminex deal
BOSTON (MarketWatch) -- Shares of Bio-Rad Laboratories jumped 12% to $115.33 Tuesday after the company announced it has extended its marketing deal with research tool-maker Luminex Corp. . Under the deal, Bio-Rad will be ...
Chuck Royce adds to small-cap positions
Chuck Royce increased his Royce & Associates’ holdings in six small-cap companies and sold shares on a seventh, according to filings.
Biotech analysts lukewarm on diagnostic stocks
Biotech analysts are mixed on whether now is the time to move into stocks of diagnostic test-makers, even though many are trading at 52-week lows.
Dow, S&P reach important downside targets
Breaching Dow 10,000 is anything but positive, but the U.S. markets have reached important support points that could mark a significant intermediate-term floor.
Recap: Bio-Rad Laboratories Q1 Earnings
on Benzinga.com
What to do with the Real Estate sector?
on Zacks.com
Bio-Rad Laboratories Inc. Cl A
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Roche Holding AG | CHF229.65B | |
| Roche Holding AG Akt | CHF229.65B | |
| Thermo Fisher Scientific Inc. | $210.74B | |
| Danaher Corp. | $178.9B | |
| Abbott Laboratories | $193.48B | |
| Merck & Co. Inc. | $298.74B | |
| Siemens AG | €118.7B | |
| Becton Dickinson & Co. | $72.04B | |
| Agilent Technologies Inc. | $39.42B | |
| bioMerieux S.A. | €11.59B |